leisure time -WSS

leisure time

author：entertainment 2025-09-05 15:33:56 - browse：45

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： NYC plans to house migrants on an island in the East River

entertainment

WSS

Nearly a dozen Russian and Chinese ships now moving away from Alaska, officials say

Reporting on presidential health from Reagan to Trump and Biden

A new drug could help frostbite victims avoid its ravages

Elevance, SCAN deals highlight health insurer acquisition scrutiny

In 'major milestone,' FDA approves first cell therapy for solid tumors

MD Anderson's Padmanee Sharma responds to research credit suit

hotspot

leisure time

explore

How one medical school became remarkably diverse

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

State Dept. review finds Biden bears some blame for Afghanistan failures

Why workplace violence is so common in health care

Alkermes shareholders re

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Drug repurposing or repositioning? The language matters

Elevance, SCAN deals highlight health insurer acquisition scrutiny

23andMe had bad news about my health. I wish a person had delivered it

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Wikipedia

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Weight loss drugs aren’t covered by Obamacare. That may change

Abridge raises $150m as clinical notes automation market heats up

Measles policy set amid Florida outbreak alarms vaccine proponents

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

explore

entertainment

entertainment

hotspot